Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Abstract Background Although sorafenib is the global standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC), it does not have reliable predictive or prognostic biomarkers. Circulating cell-free DNA (cfDNA) has shown promise as a biomarker for various cancers. We inves...

Full description

Bibliographic Details
Main Authors: Chung Ryul Oh, Sun-Young Kong, Hyeon-Su Im, Hwa Jung Kim, Min Kyeong Kim, Kyong-Ah Yoon, Eun-Hae Cho, Ja-Hyun Jang, Junnam Lee, Jihoon Kang, Sook Ryun Park, Baek-Yeol Ryoo
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma
Circulating cell-free DNA
Sorafenib
Biomarker
Genome-wide copy number alteration
Vascular endothelial growth factor-a
Online Access:http://link.springer.com/article/10.1186/s12885-019-5483-x

Internet

http://link.springer.com/article/10.1186/s12885-019-5483-x

Similar Items